22 May 2013
Keywords: ariad, updates, ap23573, trials, firm, pharmaceuticals, says
Article | 19 February 2007
US firm Ariad Pharmaceuticals says that the Phase III clinical trial of oral AP23573, its novel mTOR inhibitor, will be ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
19 February 2007
21 May 2013
© 2013 thepharmaletter.com